{"product_id":"flgt-pestle-analysis","title":"(FLGT) Fulgent Genetics, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Fulgent Genetics, Inc. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces impact the company and is useful for investors, strategists, and researchers. The page includes a real preview\/sample so you can assess style and depth before buying. Purchase the full report to receive the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS reimbursement policy for molecular diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS reimbursement policy is a key driver for Fulgent Genetics, Inc. because Medicare and commercial payer decisions can swing test volume and margins fast. Oncology panels, carrier screening, and whole genome tests often need prior authorization and medical-necessity proof, so even small coverage changes can shift revenue mix. In 2024, Fulgent Genetics, Inc. reported about $276 million in revenue, showing how payer rules can move a mid-size diagnostics business quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState lab oversight across 50 states\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. must navigate lab licensing and reporting rules across all 50 states, plus federal CLIA requirements, when it serves patients outside its home market. That adds compliance cost and slows scaling, but it also lets the Company reach a much wider national patient base. In practice, every new state can bring different clinical lab rules, so administrative work rises even as access expands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health spending after COVID-19\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic health spending still supports Fulgent Genetics, Inc. through outbreak readiness and surveillance work, but demand is uneven and tied to annual budget cycles. U.S. federal COVID-19 preparedness funding has dropped from emergency peaks, yet agencies still fund high-throughput testing and monitoring, including CDC biosurveillance programs and state lab contracts. That can still bring short, contract-based revenue swings for a diversified lab.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCalifornia policy exposure at Temple City\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTemple City puts Fulgent Genetics, Inc. in California, where healthcare rules are strict and costs run high. California's 2025 minimum wage is $16.50 an hour, and local labor and privacy rules can lift admin burden and workflow friction.\u003c\/p\u003e\n\u003cp\u003eThat said, the state also gives access to major hospital systems, UC\/Stanford talent, and a large biotech base, which helps hiring and testing partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh compliance cost\u003c\/li\u003e\n\u003cli\u003ePrivacy and labor pressure\u003c\/li\u003e\n\u003cli\u003eStrong talent and hospital access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGovernment cancer-screening initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment cancer-screening programs keep demand for early-detection tests high, and that supports blood-based and genomic oncology testing for Fulgent Genetics, Inc. U.S. policy already backs routine screening, including colorectal screening from age 45 to 75, so partnerships with health systems and public agencies can speed assay adoption and may lift reimbursement odds as evidence builds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic screening policy lifts test demand.\u003c\/li\u003e\n\u003cli\u003eAgency ties can speed adoption.\u003c\/li\u003e\n\u003cli\u003eCoverage can improve with evidence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent’s Political Risk: Payer Rules, Wage Floors, and Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for Fulgent Genetics, Inc. stays centered on U.S. payer rules, state lab licensing, and federal public-health funding. In 2025, the Company still depended on Medicare, Medicaid, and commercial coverage decisions to support test volume, while California’s $16.50 minimum wage and strict privacy rules kept compliance costs high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003eAbout $276 million in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalifornia wage floor\u003c\/td\u003e\n\u003ctd\u003e$16.50 per hour in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore policy risk\u003c\/td\u003e\n\u003ctd\u003ePayer coverage and prior auth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating burden\u003c\/td\u003e\n\u003ctd\u003e50-state lab compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces shape Fulgent Genetics, Inc.’s market risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Fulgent Genetics PESTLE snapshot that simplifies external risk review and speeds strategy discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, SEC filings, and peer-reviewed studies so investors can quickly verify Fulgent Genetics' market, pricing, and competitive assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2026 payer pressure on test pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, CMS kept pressure on lab pricing through CLFS cuts that can reach 15% a year under PAMA rules, and commercial payers are asking for stronger proof of clinical utility before broad coverage. For Fulgent Genetics, Inc., that means unit prices can fall even when demand holds. Margins stay tight unless test volume and automation rise fast enough to offset lower reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue mix beyond COVID-19 testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs COVID-19 testing normalized, Fulgent Genetics, Inc. leaned more on oncology, carrier screening, exome, genome, and rare-disease tests to spread revenue risk. That broader mix reduces reliance on pandemic demand and supports steadier clinical sales. Diversification matters because non-COVID testing is now the core growth driver, not a one-off surge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare spending tied to employment and income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. depends partly on employer and consumer healthcare budgets, so softer hiring and wage growth can slow discretionary testing. In the U.S., 2025 employer coverage still drives care for about 154 million people, but budget pressure can trim direct-to-consumer volume and elective screens. Medically necessary oncology and NICU testing usually holds up better, since these tests are tied to urgent care, not spending moods.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh reagent and logistics costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSequencing and PCR depend on specialty reagents, enzymes, and cold-chain transport, so even small price swings can squeeze Fulgent Genetics, Inc. margins. In a lab cost base, inflation in reagents, freight, and skilled staff can hit gross profit fast, especially when samples must stay at -20°C to -80°C. Scale and long supplier contracts help lock in pricing and reduce waste.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized consumables raise unit costs.\u003c\/li\u003e\n\u003cli\u003eCold-chain shipping adds fee pressure.\u003c\/li\u003e\n\u003cli\u003eLabor inflation can cut margins.\u003c\/li\u003e\n\u003cli\u003eBulk buying improves cost control.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital needs for R\u0026amp;D and commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBlood-based cancer detection and advanced genomic assays need sustained R\u0026amp;D, lab validation, and FDA\/clinical launch spend before sales ramp. For Fulgent Genetics, Inc., that means cash burn can stay high even when demand is building, so tight capital allocation matters in a business where product cycles can outlast near-term revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D comes before revenue.\u003c\/li\u003e\n\u003cli\u003eValidation and launch use cash.\u003c\/li\u003e\n\u003cli\u003eCapital discipline protects margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent Faces Medicare Pricing Pressure as Oncology Growth Takes Hold\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Medicare CLFS cuts of up to 15% under PAMA kept pressure on Fulgent Genetics, Inc. pricing, while payer demand for proof of clinical utility slowed coverage gains. Revenue mix is shifting toward oncology, exome, genome, and rare-disease tests, which helps offset COVID-19 normalization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLFS cuts\u003c\/td\u003e\n\u003ctd\u003eUp to 15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployer coverage\u003c\/td\u003e\n\u003ctd\u003e154 million lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore risk\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eFulgent Genetics, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis of Fulgent Genetics, Inc. you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging population and cancer incidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder populations are lifting cancer demand: WHO estimates 20 million new cases and 9.7 million deaths worldwide in 2022, and cases rise sharply with age. That trend supports more oncology profiling and molecular testing for Fulgent Genetics, Inc. Cancer awareness is also pushing broader panels and targeted diagnostics, which helps sustain long-term precision medicine demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNICU and PICU genomic testing demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNICU and PICU demand for genomic testing is rising as rapid whole-genome sequencing can return answers in 24 to 72 hours and has shown diagnostic yields near 20% to 40% in critically ill infants. Families and clinicians now expect faster clarity on rare and inherited conditions, and shorter turnaround times can change treatment, drug choice, and ICU length of stay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarrier screening and family planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeacon carrier screening fits the rise in reproductive genetics: the ACMG recommends carrier screening for all pregnant people, and ACOG says expanded screening is now routine in many practices. With about 3% to 4% of babies born with a genetic disorder, more couples want risk data before or during pregnancy, which supports wider adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConsumer interest in direct-to-patient genetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePicture Genetics reflects rising demand for patient-initiated testing, as consumers want quick access to ancestry, carrier risk, and health data without a clinic visit. In the U.S., 23andMe said it had 15 million+ customers, showing scale for direct-to-patient genetics. Adoption still depends on trust, plain-language results, and pricing, because unclear reports or high out-of-pocket costs slow use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConvenience drives first use\u003c\/li\u003e\n\u003cli\u003eTrust drives repeat use\u003c\/li\u003e\n\u003cli\u003eClear reports reduce hesitation\u003c\/li\u003e\n\u003cli\u003eAffordable pricing expands reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrivacy and genetic counseling expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients are more sensitive than ever to genetic-data storage and sharing, so Fulgent Genetics, Inc. must keep privacy controls tight. Clear counseling and plain-language result reviews cut fear and misreadings, which matters because one confusing report can damage trust fast. Strong consent, secure handling, and easy-to-understand follow-up help keep testing credible.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrivacy drives test adoption.\u003c\/li\u003e\n\u003cli\u003eCounseling lowers anxiety.\u003c\/li\u003e\n\u003cli\u003eClear results build trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFast-Growing Demand Drives Oncology, NICU, and Consumer Genetics Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOlder, more health-aware patients keep pushing oncology and rare-disease testing, and WHO counted 20 million new cancer cases in 2022. Demand also rises as families expect faster answers in NICU and PICU cases, where rapid whole-genome sequencing can return results in 24 to 72 hours.\u003c\/p\u003e\n\u003cp\u003eCarrier screening is now more normal in pregnancy care, and ACMG recommends screening for all pregnant people. Consumer genetics also stays relevant, with 23andMe reporting 15 million+ customers, so trust, privacy, and clear reports remain key.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer\u003c\/td\u003e\n\u003ctd\u003e20 million new cases, 2022\u003c\/td\u003e\n\u003ctd\u003eMore oncology testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNICU\/PICU\u003c\/td\u003e\n\u003ctd\u003e24 to 72 hours\u003c\/td\u003e\n\u003ctd\u003eFaster clinical decisions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer genetics\u003c\/td\u003e\n\u003ctd\u003e15 million+ customers\u003c\/td\u003e\n\u003ctd\u003eShows market scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGS platform across oncology and rare disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNGS is the core of Fulgent Genetics, Inc.'s model, powering whole exome, whole genome, and large oncology panels. In 2025, sequencing used in precision oncology kept expanding as U.S. cancer cases were projected at about 2.0 million, lifting demand for fast, accurate tumor profiling. Better throughput and lower per-sample cost strengthen Fulgent Genetics, Inc.'s edge in rare disease and cancer testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid whole genome testing in 1-3 days\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRapid whole genome testing in 1-3 days is a key edge for Fulgent Genetics, Inc. in NICU and PICU care, where fast answers can change antibiotics, surgery timing, and care plans for critically ill infants. Published neonatal studies have shown diagnostic yields near 20% to 40% for rapid genomic testing, and earlier diagnosis can cut ICU stays by days. The speed depends on high automation, strong bioinformatics, and tight lab workflow integration, so turnaround time is as important as sequencing accuracy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood-based early cancer detection with Helio Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.'s Helio Health tie-up targets noninvasive cancer detection from blood, which broadens the business beyond tissue testing and sequencing. The move can open a larger screening market, but it only works if the assay proves strong sensitivity and specificity in real-world use. Clinical validation and physician adoption will decide whether this becomes a meaningful growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-modality lab stack: RT-PCR, antigen, FISH, IHC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. is not a pure sequencing play; its lab stack spans RT-PCR, antigen, FISH, and IHC, so it can serve both infectious-disease and oncology workflows. That breadth matters for hospitals and reference labs because one vendor can support acute testing, pathology workups, and reflex follow-up in the same network.\u003c\/p\u003e\n\u003cp\u003eRT-PCR and antigen testing fit high-volume infectious disease demand, while FISH and IHC support tumor profiling and tissue diagnostics. This mix reduces reliance on a single test line and helps Fulgent sell into broader lab budgets, which is useful when buyers want one platform for multiple care paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRT-PCR: infectious disease core\u003c\/li\u003e\n\u003cli\u003eAntigen: rapid front-end screening\u003c\/li\u003e\n\u003cli\u003eFISH: oncology genetic signals\u003c\/li\u003e\n\u003cli\u003eIHC: tissue-based pathology support\u003c\/li\u003e\n\u003cli\u003eMulti-test menu broadens hospital reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBioinformatics and variant interpretation pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. depends on bioinformatics pipelines to call and classify variants, because diagnostic accuracy and report speed hinge on software quality. In 2025, Fulgent Genetics, Inc. reported revenue of $275.7 million, so faster, more reliable interpretation directly affects throughput and margins. As gene knowledge expands, algorithms need constant updates to keep variant calls clinically useful.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVariant calls drive diagnosis quality\u003c\/li\u003e\n\u003cli\u003eBetter software cuts report delays\u003c\/li\u003e\n\u003cli\u003eModel updates are ongoing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent’s Fast Genomics Powers Growth in Oncology and Infectious Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. depends on NGS, rapid genome reads, and bioinformatics to keep turnaround fast and variant calls accurate. In 2025, revenue was $275.7 million, so software quality and lab automation still matter for margin and scale. Its broad menu, from RT-PCR to FISH and IHC, helps it serve oncology and infectious-disease workflows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$275.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRapid WGS\u003c\/td\u003e\n\u003ctd\u003e1-3 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. 2025 cancer cases\u003c\/td\u003e\n\u003ctd\u003e~2.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA and CAP laboratory compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.’s clinical testing depends on CLIA and CAP controls for validation, proficiency testing, and report accuracy, and CAP inspections typically recur every 2 years. Any lapse can trigger license risk, lower payor trust, and disrupt service continuity. For a diagnostics lab, compliance is not back-office work; it is the license to operate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA scrutiny of lab-developed tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA scrutiny of lab-developed tests is a key legal risk for Fulgent Genetics, Inc., because the FDA finalized a 4-year phaseout of enforcement discretion in May 2024. That rule can raise validation, labeling, and documentation costs, especially for novel genomic assays. For a lab with 2024 revenue of $284.4 million, tighter review can also slow launches and add compliance spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIPAA protection of genetic data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. handles genetic data that HIPAA treats as highly sensitive protected health information, so it needs tight controls on access, transmission, and storage. OCR can fine HIPAA violations up to about $2.1 million per violation category, and a major breach can also trigger class-action risk and lasting trust loss. For a genetics lab, even one weak link in file sharing or cloud storage can turn into legal and revenue damage fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayer audits and medical-necessity reviews\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsurers routinely audit molecular claims, and medical-necessity evidence must match the billed test and patient indication. For Fulgent Genetics, Inc., that makes clean order records, ICD-10 linkage, and assay-level documentation critical, because mismatches can trigger denials, recoupments, and delayed cash collection.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMatch test, diagnosis, and chart notes.\u003c\/li\u003e\n\u003cli\u003eKeep prior-auth and order trails.\u003c\/li\u003e\n\u003cli\u003eUse strong billing controls to cut recoupments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent, license, and partnership agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiagnostic innovation at Fulgent Genetics, Inc. depends on patents, licenses, and partner contracts that protect test design, data use, and revenue rights. In its latest 2025 filings, legal control over IP still matters because it shapes who can build, sell, and share income from new assays.\u003c\/p\u003e\n\u003cp\u003ePartnerships such as Helio Health need clear terms on ownership, commercialization, and royalties so product development does not stall. A clean legal split lowers dispute risk and helps Fulgent Genetics, Inc. move faster from R\u0026amp;D into revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtects assay IP and test methods\u003c\/li\u003e\n\u003cli\u003eSets clear commercialization rights\u003c\/li\u003e\n\u003cli\u003eReduces royalty and ownership disputes\u003c\/li\u003e\n\u003cli\u003eSupports faster revenue sharing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent Faces Rising FDA and Privacy Compliance Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk for Fulgent Genetics, Inc. centers on CLIA\/CAP lab rules, FDA oversight of lab-developed tests, HIPAA data privacy, and payer audits. The biggest current shift is the FDA’s May 2024 move to phase out enforcement discretion over 4 years, which can raise validation and compliance costs. In 2024, revenue was $284.4 million, so delays or denials can hurt cash flow fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA LDT phaseout\u003c\/td\u003e\n\u003ctd\u003e4 years, May 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA penalty\u003c\/td\u003e\n\u003ctd\u003eAbout $2.1 million per category\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e$284.4 million, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy-intensive laboratory operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc.'s sequencing and clinical labs run on continuous power and tight temperature control, so energy use stays high. Ultra-low freezers can draw about 15 to 20 kWh a day each, and HVAC often takes 40% to 60% of a lab's electricity load. Better motors, LEDs, and workflow automation can cut both operating costs and Scope 2 emissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomedical and hazardous waste handling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. generates regulated waste from specimens, reagents, and disposables, and about 15% of healthcare waste is hazardous, so segregation at the bench matters. Proper containerization, labeling, and licensed disposal help meet safety rules and avoid spill or exposure risk. Better waste control also cuts landfill load and lowers the lab’s environmental footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain shipping and sample transport\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany Fulgent Genetics, Inc. assays depend on samples arriving in 24–48 hours and staying at 2–8°C or frozen at -20°C\/-80°C, so shipping delays can damage integrity. Cold-chain logistics also add more insulated packaging, gel packs, and dry ice, which raises waste and transport emissions. Reliable courier pickup and tracking matter because even small temperature breaks can ruin results and force recollection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply-chain disruption from climate events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExtreme weather can delay reagent deliveries and specimen transport, so Fulgent Genetics, Inc. may face longer turnaround times and uneven service continuity across regions. U.S. billion-dollar weather disasters have already hit 28 events in 2023 and 27 in 2024, showing how often logistics can be disrupted. Business continuity plans, backup couriers, and redundant lab routing are key for a distributed lab network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeather can slow shipping\u003c\/li\u003e\n\u003cli\u003eTurnaround times can slip\u003c\/li\u003e\n\u003cli\u003eRedundancy protects service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSustainability expectations from hospitals and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and payers increasingly screen lab vendors on sustainability, not just price. U.S. health care drives about 8.5% of national greenhouse gas emissions, so lower-waste workflows, lean packaging, and tighter resource use can help Fulgent Genetics, Inc. win bids and renewals. Environmental performance is now part of long-term supplier scorecards, so cleaner operations can support stickier contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower waste can lift procurement scores\u003c\/li\u003e\n\u003cli\u003eEfficient resource use can cut costs\u003c\/li\u003e\n\u003cli\u003eESG metrics can influence renewals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent’s Lab Power and Cold-Chain Risks Shape Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent Genetics, Inc. faces high electricity use from 24\/7 lab operations, with HVAC often 40% to 60% of lab power and ultra-low freezers at 15 to 20 kWh a day each. Cold-chain shipping, dry ice, and weather delays can raise emissions and disrupt 24–48 hour sample windows. Waste segregation and greener sourcing can lower costs and supplier risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eEnvironmental factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab power use\u003c\/td\u003e\n\u003ctd\u003eHVAC 40%-60%; freezer 15-20 kWh\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain\u003c\/td\u003e\n\u003ctd\u003e2-8°C or -20°C\/-80°C needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaste\u003c\/td\u003e\n\u003ctd\u003e~15% of healthcare waste is hazardous\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234427248905,"sku":"flgt-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/flgt-pestle-analysis.webp?v=1785718839","url":"https:\/\/dcfanalyst.com\/products\/flgt-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}